Filtered By:
Therapy: Hormonal Therapy
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 218 results found since Jan 2013.
Hormone Therapy May Be OK for Women With Migraines
Heightened risk of stroke not borne out in preliminary study
Source: WebMD Health - October 11, 2017 Category: Consumer Health News Source Type: news
Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review
ConclusionsEvidence supporting bone and cardiovascular benefits of HT in women with POI is limited by high risk of bias, reliance on surrogate outcomes, and heterogeneity of trials regarding the formulation, dose, route of administration, and regimen of HT. Further research addressing patient important outcomes such as fractures, stroke, and cardiovascular mortality are crucial to optimize benefits of this therapy.
Source: Endocrine - October 16, 2017 Category: Endocrinology Source Type: research
In Defense of Progesterone: A Review of the Literature.
Conclusions • Physicians should have no hesitation prescribing natural progesterone. The evidence is clear that progesterone does not cause breast cancer. Indeed, progesterone is protective and preventative of breast cancer.
PMID: 29055286 [PubMed - as supplied by publisher]
Source: Alternative Therapies in Health and Medicine - October 21, 2017 Category: Complementary Medicine Authors: Lieberman A, Curtis L Tags: Altern Ther Health Med Source Type: research
Stopping hormone therapy increases risk of cardiac complications
According to a study, published inMenopause, discontinuing hormone therapy increases the risk of heart–related complications and stroke.News Medical
Source: Society for Endocrinology - November 9, 2017 Category: Endocrinology Source Type: news
CV Deaths in Younger Women Rise During Year After Stopping HT CV Deaths in Younger Women Rise During Year After Stopping HT
Women younger than 60 years had a higher risk for cardiac and stroke death during the first year after stopping hormone therapy compared with those not taking HT and those continuing HT, a study found.Medscape Medical News
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news
Stopping HRT after menopause may increase cardiovascular disease risk
Research published inMenopause reports that women who stop hormone therapy after menopause are at higher risk of cardiac and stroke death.Healio
Source: Society for Endocrinology - November 17, 2017 Category: Endocrinology Source Type: news
Impact of microbiota on the use and effects of isoflavones in the relief of climacteric symptoms in menopausal women – A review
Publication date: February 2018 Source:Journal of Functional Foods, Volume 41 Author(s): Naice E.S. Monteiro, Lívia D. Queirós, Danielle B. Lopes, Adriana O. Pedro, Gabriela A. Macedo Menopause is a natural event that occurs in women around the age of 50 years, causing irregularities in the menstrual cycle until its complete end, due to the hormonal deficit, especially estrogen, that causes several unpleasant urogenital and vasomotor symptoms. Hormone replacement therapy has many benefits, but should be prescribed with caution in women with a history of stroke, thromboembolic events, certain types of cancer, or increa...
Source: Journal of Functional Foods - December 22, 2017 Category: Nutrition Source Type: research
Androgens and cardiovascular risk: A series of case report in the French and Canadian pharmacovigilance databases.
CONCLUSION: Our study shows a very low report of cardiovascular effects under testosterone, all doubtful. Pending further studies, it seems reasonable to consider the cardiovascular risk of patients who are candidates for hormone therapy for age-related androgen deficiency.
LEVEL OF EVIDENCE: 3.
PMID: 29650456 [PubMed - as supplied by publisher]
Source: Progres en Urologie - April 15, 2018 Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Hormone therapy in transgender women may deteriorate cardiovascular health
Hormone treatment given to transgender patients transitioning from male to female may significantly increase their risk of stroke, a study inAnnals of Internal Medicine reports. Reuters
Source: Society for Endocrinology - July 10, 2018 Category: Endocrinology Source Type: news
Heart Risks Tied to Transwomen ' s Hormone Therapy
TUESDAY, July 10, 2018 -- Transwomen who undergo hormone therapy may face higher chances of blood clots, stroke and heart attack, a new study suggests.
The term transwoman refers to a woman who is designated male at birth. Some undergo hormone...
Source: Drugs.com - Daily MedNews - July 10, 2018 Category: General Medicine Source Type: news
Hormone therapy in menopausal women with fibroids: is it safe?
Menopause is an important transition in the life of women. It has been estimated that by the year 2030, worldwide 1.2 billion women will be menopausal. The most bothersome symptoms of menopause are believed to be due to declines in estrogen levels in postmenopausal women. Thus, hormone therapy is an effective treatment option for menopausal women, although prolonged use of hormone therapy is associated with a slightly increased risk of breast cancer, thromboembolism, and stroke. A literature search for studies evaluating the effects of hormone therapy in menopausal women with asymptomatic fibroids demonstrated variable eff...
Source: Menopause - July 26, 2018 Category: OBGYN Tags: Personal Perspective Source Type: research
Pattern of mortality after menopausal hormone therapy: long-term follow-up in a population based cohort.
CONCLUSIONS: In this long-term follow-up study, taking hormones during menopause was not associated with overall mortality among middle-aged women. Investigating cause-specific mortality revealed significant albeit weak associations differential according to both causes of death and over time underlining the importance of carefully considering individual risks and duration of treatment when making decisions on hormone therapy. This article is protected by copyright. All rights reserved.
PMID: 30106241 [PubMed - as supplied by publisher]
Source: BJOG : An International Journal of Obstetrics and Gynaecology - August 14, 2018 Category: OBGYN Authors: Holm M, Olsen A, Au Yeung SL, Overvad K, Lidegaard Ø, Kroman N, Tjønneland A Tags: BJOG Source Type: research
The 2017 hormone therapy position statement of The North American Menopause Society
The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel's recommendations were reviewed and approved by...
Source: Menopause - October 25, 2018 Category: OBGYN Tags: Commemorative Papers Source Type: research
Hormone Therapy Linked to CV Risk During Gender Transition Hormone Therapy Linked to CV Risk During Gender Transition
Transgender hormone therapy is associated with an increased risk for MI, stroke, and venous thromboembolism, underscoring the importance of patient counseling and close monitoring in this population.Medscape Medical News
Source: Medscape Medical News Headlines - February 20, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news
MHT in myocardial infarction and stroke survivors
30 years ago, it was believed that there is a clear cut protective effect of estrogen in women with coronary artery disease. This was based on studies that monitored the outcomes of postmenopausal hormone therapy (MHT) in women with various basal clinical scenarios, such as myocardial infarction, coronary angiography or coronary artery bypass. These studies were observational, and treatment usually comprised of conjugated equine estrogen alone or combined with medroxyprogesterone acetate. However, results of randomized, placebo-controlled trials (secondary prevention, but mainly primary prevention) pointed at neutrality or...
Source: Maturitas - May 14, 2019 Category: Primary Care Authors: Amos Pines Tags: INV25 Source Type: research
